Targeting MALT1 for the treatment of diffuse large B-cell lymphoma

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–1874. Dec 17
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836–4843.
   PubMed Web of Science ®Google Scholar
• Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568.e14.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Rebeaud F, Hailfinger S, Posevitz-Fejfar A, et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol. 2008;9(3):272–281. Mar
   PubMed Web of Science ®Google Scholar
• Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science. 2003;302(5650):1581–1584. Nov 28
   PubMed Web of Science ®Google Scholar
• Ruland J, Duncan GS, Wakeham A, et al. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity. 2003;19(5):749–758.
   PubMed Web of Science ®Google Scholar
• Ruland J, Hartjes L. CARD-BCL-10-MALT1 signalling in protective and pathological immunity. Nat Rev Immunol. 2019;19(2):118–134.
   PubMed Web of Science ®Google Scholar
• Juilland M, Thome M. Holding all the CARDs: how MALT1 controls CARMA/CARD-dependent signaling. Front Immunol. 2018;9:1927.
   PubMed Web of Science ®Google Scholar
• Sommer K, Guo B, Pomerantz JL, et al. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity. 2005;23(6):561–574.
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Wang D, Blonska M, et al. Phosphorylation of CARMA1 plays a critical role in T cell receptor-mediated NF-kappaB activation. Immunity. 2005;23(6):575–585.
   PubMed Web of Science ®Google Scholar
• Satpathy S, Wagner SA, Beli P, et al. Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation. Mol Syst Biol. 2015;11(6):810.
   PubMed Web of Science ®Google Scholar
• Sun L, Deng L, Ea CK, et al. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell. 2004;14(3):289–301.
   PubMed Web of Science ®Google Scholar
• Oeckinghaus A, Wegener E, Welteke V, et al. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J. 2007;26(22):4634–4645.
   PubMed Web of Science ®Google Scholar
• Blonska M, Pappu BP, Matsumoto R, et al. The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity. 2007;26(1):55–66.
   PubMed Web of Science ®Google Scholar
• de Gorter DJ, Vos JC, Pals ST, et al. The B cell antigen receptor controls AP-1 and NFAT activity through ras-mediated activation of Ral. J Immunol. 2007;178(3):1405–1414.
   PubMed Web of Science ®Google Scholar
• Xia X, Cao G, Sun G, et al. GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis. J Clin Invest. 2020;130(10):5180–5196.
   PubMed Web of Science ®Google Scholar
• Hailfinger S, Nogai H, Pelzer C, et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci USA. 2011;108(35):14596–14601.
   PubMed Web of Science ®Google Scholar
• Coornaert B, Baens M, Heyninck K, et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol. 2008;9(3):263–271.
   PubMed Web of Science ®Google Scholar
• Staal J, Driege Y, Bekaert T, et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J. 2011;30(9):1742–1752.
   PubMed Web of Science ®Google Scholar
• Klein T, Fung SY, Renner F, et al. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling. Nat Commun. 2015;6:8777.
   PubMed Web of Science ®Google Scholar
• Jeltsch KM, Hu D, Brenner S, et al. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation. Nat Immunol. 2014;15(11):1079–1089.
   PubMed Web of Science ®Google Scholar
• Fontán L, Qiao Q, Hatcher JM, et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J Clin Invest. 2018;128(10):4397–4412.
   PubMed Web of Science ®Google Scholar
• Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101(6):2335–2339.
   PubMed Web of Science ®Google Scholar
• Rosebeck S, Madden L, Jin X, et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science. 2011;331(6016):468–472.
   PubMed Web of Science ®Google Scholar
• Xia M, David L, Teater M, et al. BCL10 gain-of-Function mutations aberrantly induce canonical and non-canonical NF-Kb activation and resistance to ibrutinib in ABC-DLBCL. Blood. 2020;136(1):2–3.
   Google Scholar
• Phelan JD, Young RM, Webster DE, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560(7718):387–391.
   PubMed Web of Science ®Google Scholar
• Juilland M, Gonzalez M, Erdmann T, et al. CARMA1- and MyD88-dependent activation of jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Blood. 2016;127(14):1780–1789.
   PubMed Web of Science ®Google Scholar
• Xia X, Zhou W, Guo C, et al. Glutaminolysis mediated by MALT1 protease activity facilitates PD-L1 expression on ABC-DLBCL cells and contributes to their immune evasion. Front Oncol. 2018;8:632.
   PubMed Web of Science ®Google Scholar
• Blonska M, Zhu Y, Chuang HH, et al. Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood. 2015;125(6):981–991.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926.
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Bartlett NL, Blum KA, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016;54:11–17.
   PubMed Web of Science ®Google Scholar
• Lenz G, Hawkes E, Verhoef G, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34(8):2184–2197.
   PubMed Web of Science ®Google Scholar
• Demeyer A, Van Nuffel E, Baudelet G, et al. MALT1-deficient mice develop atopic-like dermatitis upon aging. Front Immunol. 2019;10:2330.
   PubMed Web of Science ®Google Scholar
• Fontán L, Yang C, Kabaleeswaran V, et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 2012;22(6):812–824.
   PubMed Web of Science ®Google Scholar
• Scott DA, Hatcher JM, Liu H, et al. Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Bioorg Med Chem Lett. 2019;29(14):1694–1698.
   PubMed Web of Science ®Google Scholar
• Pissot Soldermann C, Simic O, Renatus M, et al. Discovery of potent, highly selective, and in vivo efficacious, allosteric MALT1 inhibitors by iterative scaffold morphing. J Med Chem. 2020;63(23):14576–14593.
   PubMed Web of Science ®Google Scholar
• Philippar U, Lu T, Vloemans N, et al. Abstract 5690: discovery of JNJ-67856633: a novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas. Cancer Res. 2020;80:5690.
   Web of Science ®Google Scholar
• Nagel D, Bognar M, Eitelhuber AC, et al. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. Oncotarget. 2015;6(39):42232–42242.
   PubMedGoogle Scholar
• Saba NS, Wong DH, Tanios G, et al. MALT1 inhibition is efficacious in both naïve and Ibrutinib-Resistant chronic lymphocytic leukemia. Cancer Res. 2017;77(24):7038–7048.
   PubMed Web of Science ®Google Scholar
• Dai B, Grau M, Juilland M, et al. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood. 2017;129(3):333–346.
   PubMed Web of Science ®Google Scholar
• Spiniello M, Steinbrink MI, Cesnik AJ, et al. Comprehensive in vivo identification of the c-Myc mRNA protein interactome using HyPR-MS. RNA. 2019;25(10):1337–1352.
   PubMed Web of Science ®Google Scholar
• A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) [cited 2021. Jun 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03900598
   Google Scholar
• A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors [cited 2021. Aug 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT04859777
   Google Scholar
• Fontán L, Goldstein R, Casalena G, et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood. 2021;137(6):788–800.
   PubMed Web of Science ®Google Scholar
• Krönke J, Hurst SN, Ebert BL. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014;3(7):e941742.
   PubMed Web of Science ®Google Scholar
• Matyskiela ME, Lu G, Ito T, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature. 2016;535(7611):252–257.
   PubMed Web of Science ®Google Scholar
• Seshadri MR, Fontán L, Scott D, et al. MALT1 degradation for the treatment of activated B-cell type diffuse large B-cell lymphoma. Hematol Oncol. 2021;39(S2).
   Google Scholar
• Kang H, Hu D, Murai M, et al. Inhibition of BCL10-MALT1 interaction to treat diffuse large B-cell lymphoma. AACR. Cancer Res. 2020;80(16):37.
   Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135(8):523–533.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Takata K, Béguelin W, et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9(4):546–563.
   PubMed Web of Science ®Google Scholar
• Godfrey J, Tumuluru S, Bao R, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019;133(21):2279–2290.
   PubMed Web of Science ®Google Scholar
• Pascual M, Mena-Varas M, Robles EF, et al. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019;133(22):2401–2412.
   PubMed Web of Science ®Google Scholar
• Kotlov N, Bagaev A, Revuelta MV, et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021;11(6):1468–1489.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed/refractory diffuse large B-Cell lymphoma in patients ineligible for or having failed autologous transplantation: a Single-Arm, phase II study. J Clin Oncol. 2019;37(6):481–489.
   PubMed Web of Science ®Google Scholar
• Gewies A, Gorka O, Bergmann H, et al. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation. Cell Rep. 2014;9(4):1292–1305.
   PubMed Web of Science ®Google Scholar
• Jaworski M, Marsland BJ, Gehrig J, et al. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. EMBO J. 2014;33(23):2765–2781.
   PubMed Web of Science ®Google Scholar
• Punwani D, Wang H, Chan AY, et al. Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation. J Clin Immunol. 2015;35(2):135–146.
   PubMed Web of Science ®Google Scholar
• Charbit-Henrion F, Jeverica AK, Bègue B, et al. Deficiency in mucosa-associated lymphoid tissue lymphoma translocation 1: a novel cause of IPEX-Like syndrome. J Pediatr Gastroenterol Nutr. 2017;64(3):378–384.
   PubMed Web of Science ®Google Scholar
• Demeyer A, Driege Y, Skordos I, et al. Long-Term MALT1 inhibition in adult mice without severe systemic autoimmunity. iScience. 2020;23(10):101557.
   PubMed Web of Science ®Google Scholar
• Martin K, Junker U, Tritto E, et al. Pharmacological inhibition of MALT1 protease leads to a progressive IPEX-Like pathology. Front Immunol. 2020;11:745.
   PubMed Web of Science ®Google Scholar
• Brown GD, Willment JA, Whitehead L. C-type lectins in immunity and homeostasis. Nat Rev Immunol. 2018;18(6):374–389.
   PubMed Web of Science ®Google Scholar
• Rieber N, Singh A, Öz H, et al. Pathogenic fungi regulate immunity by inducing neutrophilic myeloid-derived suppressor cells. Cell Host Microbe. 2015;17(4):507–514.
   PubMed Web of Science ®Google Scholar
• Yang M, Shao JH, Miao YJ, et al. Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization. Cell Death Differ. 2014;21(8):1290–1302.
   PubMed Web of Science ®Google Scholar
• Gross O, Grupp C, Steinberg C, et al. Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production. Blood. 2008;112(6):2421–2428.
   PubMed Web of Science ®Google Scholar
• Cheng L, Deng N, Yang N, et al. Malt1 protease is critical in maintaining function of regulatory T cells and may be a therapeutic target for antitumor Immunity. J Immunol. 2019;202(10):3008–3019.
   PubMed Web of Science ®Google Scholar
• Di Pilato M, Kim EY, Cadilha BL, et al. Targeting the CBM complex causes treg cells to prime tumours for immune checkpoint therapy. Nature. 2019;570(7759):112–116.
   PubMed Web of Science ®Google Scholar
• Beider K, Besser MJ, Schachter J, et al. Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies. Blood. 2019;134(1):3234–3234.
   Web of Science ®Google Scholar
• Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385.
   PubMed Web of Science ®Google Scholar